Cost-effectiveness of implantable cardioverter defibrillators in Brazil in the public and private sectors;Custo-efetividade de cardiodesfibriladores implantáveis no Brasil nos setores público e privado

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 5, 2010, Pages 577-586

  Ribeiro, Rodrigo Antonini ^a   Stella, Steffan Frosi ^a   Zimerman, Leandro Ioschpe ^a   Pimentel, Maurício ^a   Rohde, Luis Eduardo ^a   Polanczyk, Carisi Anne ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Brazil; Cost benefit analysis; Defibrillators; Implantable

Indexed keywords

ADULT; AGED; ARTICLE; BRACHIAL THROMBOSIS; BRAZIL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; FEMALE; HEART FAILURE; HIDDEN MARKOV MODEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMOTHORAX; PRIVATE HOSPITAL; PUBLIC HOSPITAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SENSITIVITY ANALYSIS; THROMBOSIS; WORLD HEALTH ORGANIZATION;

EID: 78651471340     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000134     Document Type: Article

References (38)

1. McMurray JJ, Petrie MC, Murdoch DR, Davie A P. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P): P9-16.
2. Hoes AW, Mosterd A, Grobbee DE. An epidemic of heart failure? Recent evidence from Europe. Eur Heart J. 1998;19(Suppl L): L2-9.
3. Krum H, Stewart S. Chronic heart failure: time to recognize this major public health problem. Med J Aust. 2006;184(4):147-8.
4. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart. 2003;89(1):49-53.
5. Ministério da Saúde. Datasus. [Acesso em 2006 jun 20]. Disponível em: http:\www.datasus.gov. br.
6. Sociedade Brasileira de Cardiologia. Grupo de Estudos de Insuficiência Cardíaca (GEIC). Revisão das II Diretrizes da Sociedade Brasileira de Cardiologia para o diagnóstico e tratamento da insuficiência cardíaca. Arq Bras Cardiol. 2002;79(supl 4):1-30.
7. Moss AJ, Hall WJ, Cannom DS, Daubert J P, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933-40.
8. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83.
9. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37.
10. Al-Khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger J T, et al. Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J. 2005;149(6):1020-34.
11. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44(11):2166-72.
12. Boriani G, Biffi M, Martignani C, Camanini C, Grigioni F, Rapezzi C, et al. Cardioverter-defibrillators after MADIT-II: the balance between weight of evidence and treatment costs. Eur J Heart Fail. 2003;5(4):419-25.
13. Sanders G, Hlatky M, Owens D. Cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population. Technol Eval Cent Asses Program Exe Summ. 2004;19(3):1-26.
14. Al-Khatib SM, Anstrom KJ, Eisenstein EL, Peterson ED, Jollis JG, Mark DB, et al. Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med. 2005;142(8):593-600.
15. Zwanziger J, Hall WJ, Dick AW, Zhao H, Mushlin AI, Hahn RM, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47(11):2310-8.
16. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471-80.
17. Ribeiro RA, Stella S F, Camey SA, Zimerman LI, Pimentel M, Rohde LE, et al. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector. Value in Health. 2009. In Press. [Epub ahead of print].
18. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of costeffectiveness analysis in health and medicine: panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172-7.
19. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: panel on cost-effectiveness in health and medicine. JAMA. 1996;276(16):1339-41.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253-8.
21. Rohde LE, Beck-da-Silva L, Goldraich L, Grazziotin TC, Palombini D V, Polanczyk CA, et al. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can J Cardiol. 2004;20(7):697-702.
22. Rohde LE, Clausell N, Ribeiro J P, Goldraich L, Netto R, William Dec. G, et al. Health outcomes in decompensated congestive heart failure: a comparison of tertiary hospitals in Brazil and United States. Int J Cardiol. 2005;102(1):71-7.
23. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C, et al. Systematic review: implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251-62.
24. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28(9):926-32.
25. Schoels W, Swerdlow CD, Jung W, Stein KM, Seidl K, Haffajee CJ. Worldwide clinical experience with a new dual-chamber implantable cardioverter defibrillator system. J Cardiovasc Electrophysiol. 2001;12(5):521-8.
26. Bardy GH, Yee R, Jung W. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators. J Am Coll Cardiol. 1996;28(2):400-10.
27. Takahashi T, Bhandari AK, Watanuki M, Cannom DS, Sakurada H, Hiraoka M. High incidence of device-related and lead-related complications in the dual-chamber implantable cardioverter defibrillator compared with the single-chamber version. Circ J. 2002;66(8):746-50.
28. Bansch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105(12):1453-8.
29. Rosenqvist M, Beyer T, Block M, den Dulk K, Minten J, Lindemans F. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation. 1998;98(7):663-70.
30. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474-80.
31. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med. 2001;135(10):870-83.
32. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135-42.
33. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J. 2002;144(3):440-8.
34. Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, et al. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of costeffectiveness and cost-utility for these groups in a UK context. Health Technol Assess. 2006;10(27): iii-iv, ix-xi, 1-164.
35. Chen L, Hay J W. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004;18(2):161-70.
36. Araujo D V, Tavares LR, Verissimo R, Ferraz MB, Mesquita E T. Cost of heart failure in the Unified Health System. Arq Bras Cardiol. 2005;84(5):422-7.
37. Bryant J, Brodin H, Loveman E, Clegg A. Clinical effectiveness and costeffectiveness of implantable cardioverter defibrillators for arrhythmias: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23(1):63-70.
38. Neyt M, Thiry N, Ramaekers D, Van Brabandt H. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy. 2008;6(1):67-80.